Rocco A. Montone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5477256/publications.pdf

Version: 2024-02-01

201385 205818 2,665 111 27 48 citations h-index g-index papers 119 119 119 3355 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Redefining residual inflammatory risk after acute coronary syndrome. Future Cardiology, 2022, 18, 115-123.	0.5	2
2	Air Pollution and Coronary Plaque Vulnerability and Instability. JACC: Cardiovascular Imaging, 2022, 15, 325-342.	2.3	30
3	Pathophysiology of Coronary Microvascular Dysfunction. Circulation Journal, 2022, 86, 1319-1328.	0.7	40
4	Bleeding Complications in Patients With Perioperative COVID-19 Infection Undergoing Cardiac Surgery: A Single-Center Matched Case-Control Study. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 1919-1926.	0.6	11
5	Molecular Hallmarks of Ischemia with Non-Obstructive Coronary Arteries: The "INOCA versus Obstructive CCS―Challenge. Journal of Clinical Medicine, 2022, 11, 1711.	1.0	5
6	Takotsubo Syndrome in Intensive Cardiac Care Unit: Challenges in Diagnosis and Management. Current Problems in Cardiology, 2022, 47, 101084.	1.1	6
7	Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nature Reviews Cardiology, 2022, 19, 684-703.	6.1	106
8	Coronary Microvascular Dysfunction IsÂAssociated With a Worse Cardiac Phenotype in Patients With Fabry Disease. JACC: Cardiovascular Imaging, 2022, 15, 1518-1520.	2.3	3
9	Diagnostic work-up and therapeutic implications in MINOCA: need for a personalized approach. Future Cardiology, 2021, 17, 149-154.	0.5	17
10	Human monocyte-derived macrophages: Pathogenetic role in plaque rupture associated to systemic inflammation. International Journal of Cardiology, 2021, 325, 1-8.	0.8	3
11	Brain-derived neurotrophic factor in patients with acute coronary syndrome. Translational Research, 2021, 231, 39-54.	2.2	6
12	Direct oral anticoagulants vs. vitamin K antagonists for the treatment of left ventricular thrombosis: a systematic review of the literature and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e21-e25.	1.4	16
13	Coronary provocative tests in the catheterization laboratory: Pathophysiological bases, methodological considerations and clinical implications. Atherosclerosis, 2021, 318, 14-21.	0.4	30
14	Clinical predictors and prognostic role of high Killip class in patients with a first episode of anterior ST-segment elevation acute myocardial infarction. Journal of Cardiovascular Medicine, 2021, 22, 530-538.	0.6	11
15	Recurrent asymptomatic Takotsubo syndrome after 20 years: are we looking at the tip of the iceberg only?. Future Cardiology, 2021, 17, 309-314.	0.5	1
16	Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e69-e70.	1.4	30
17	The central role of invasive functional coronary assessment for patients with ischemic heart disease. International Journal of Cardiology, 2021, 331, 17-25.	0.8	7
18	Interplay Between Myocardial Bridging and Coronary Spasm in Patients With Myocardial Ischemia and Nonâ€Obstructive Coronary Arteries: Pathogenic and Prognostic Implications. Journal of the American Heart Association, 2021, 10, e020535.	1.6	36

#	Article	IF	CITATIONS
19	Left ventricular end-diastolic pressure predicts in-hospital outcomes in takotsubo syndrome. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 661-667.	0.4	10
20	Interplay between inflammation and microvascular obstruction in ST-segment elevation myocardial infarction: The importance of velocity. International Journal of Cardiology, 2021, 339, 7-9.	0.8	4
21	Coronary Microvascular Dysfunction Across the Spectrum of CardiovascularÂDiseases. Journal of the American College of Cardiology, 2021, 78, 1352-1371.	1.2	201
22	The evolving role of cardiac imaging in patients with myocardial infarction and non-obstructive coronary arteries. Progress in Cardiovascular Diseases, 2021, 68, 78-87.	1.6	17
23	Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 633-642.	0.4	3
24	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrial fibrillation: the (ORIGAMI) study. Journal of Cardiovascular Medicine, 2021, 22, 175-179.	0.6	3
25	Predictors of fractional flow reserve/instantaneous wave-free ratio discordance. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 106-115.	0.6	1
26	A Novel Monocyte Subset as a Unique Signature of Atherosclerotic Plaque Rupture. Frontiers in Cell and Developmental Biology, 2021, 9, 753223.	1.8	7
27	Monocyte-Platelet Aggregates Triggered by CD31 Molecule in Non-ST Elevation Myocardial Infarction: Clinical Implications in Plaque Rupture. Frontiers in Cardiovascular Medicine, 2021, 8, 741221.	1.1	2
28	The Role of Cardiac Magnetic Resonance in Myocardial Infarction and Non-obstructive Coronary Arteries. Frontiers in Cardiovascular Medicine, 2021, 8, 821067.	1.1	13
29	Myocardial infarction with non-obstructive coronary arteries: dealing with pears and apples. European Heart Journal, 2020, 41, 879-881.	1.0	17
30	Clinical, angiographic and echocardiographic correlates of epicardial and microvascular spasm in patients with myocardial ischaemia and non-obstructive coronary arteries. Clinical Research in Cardiology, 2020, 109, 435-443.	1.5	35
31	Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 128-129.	1.4	19
32	Aspirin in primary prevention of cardiovascular disease in the elderly. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 326-327.	1.4	2
33	Special Article - Emotional versus physical Takotsubo syndrome: Two faces of the same medal or two different syndromes?. Progress in Cardiovascular Diseases, 2020, 63, 699-701.	1.6	11
34	Management of non-culprit coronary plaques in patients with acute coronary syndrome. European Heart Journal, 2020, 41, 3579-3586.	1.0	29
35	Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology. Current Cardiology Reports, 2020, 22, 102.	1.3	10
36	Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103074.	2.0	12

#	Article	IF	CITATIONS
37	Macrophage infiltrates in coronary plaque erosion and cardiovascular outcome in patients with acute coronary syndrome. Atherosclerosis, 2020, 311, 158-166.	0.4	20
38	Role of endothelial dysfunction in determining angina after percutaneous coronary intervention: Learning from pathophysiology to optimize treatment. Progress in Cardiovascular Diseases, 2020, 63, 233-242.	1.6	13
39	Coronary slow flow is associated with a worse clinical outcome in patients with Takotsubo syndrome. Heart, 2020, 106, 923-930.	1.2	36
40	Myocardial and Microvascular Injury Due to Coronavirus Disease 2019. European Cardiology Review, 2020, 15, e52.	0.7	35
41	Optimized Treatment of ST-Elevation Myocardial Infarction. Circulation Research, 2019, 125, 245-258.	2.0	140
42	Recurrence of angina after ST-segment elevation myocardial infarction: the role of coronary microvascular obstruction. European Heart Journal: Acute Cardiovascular Care, 2019, , 2048872619880661.	0.4	2
43	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2019, 10, 1347.	1.3	81
44	Response by Montone et al to Letter Regarding Article, "Optimized Treatment of ST-Elevation Myocardial Infarction― Circulation Research, 2019, 125, e30.	2.0	0
45	Optical coherence tomography and C-reactive protein in risk stratification of acute coronary syndromes. International Journal of Cardiology, 2019, 286, 7-12.	0.8	13
46	Changes in renal function and occurrence of contrast-induced nephropathy after percutaneous coronary interventions in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants or warfarin. Postepy W Kardiologii Interwencyjnej, 2019, 15, 59-67.	0.1	2
47	Takotsubo syndrome and left ventricular non-compaction cardiomyopathy: Casualty or causality?. Autonomic Neuroscience: Basic and Clinical, 2019, 218, 64-67.	1.4	2
48	$154 \hat{a} \in$ Recurrence of angina after ST-elevation myocardial infarction: the role of microvascular obstruction. , $2019,$, .		0
49	Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 105-116.	1.4	44
50	Percutaneous treatment of an iatrogenic pseudoaneurism of the aortic Valsalva sinus. European Heart Journal, 2018, 39, ehw661.	1.0	0
51	Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. European Heart Journal, 2018, 39, 91-98.	1.0	164
52	Drug eluting versus bare metal stents for percutaneous coronary intervention of saphenous vein graft lesions: An updated meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine, 2018, 19, 837-844.	0.3	2
53	Periprocedural Myocardial Injury Predicts Short- and Long-Term Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e007106.	1.4	22
54	Predictive value of C-reactive protein after drug-eluting stent implantation: an update view. Future Cardiology, 2018, 14, 355-358.	0.5	2

#	Article	IF	Citations
55	Role of Allergic Inflammatory Cells in Coronary Artery Disease. Circulation, 2018, 138, 1736-1748.	1.6	61
56	The coronary sinus Reducer device for refractory chronic angina: rationale, clinical evidence and future perspectives. Expert Review of Medical Devices, 2018, 15, 611-613.	1.4	0
57	Reconsidering aetiologies of type 2 myocardial infarction: when a classification is a simplistic approach for a complex reality. European Heart Journal, 2018, 39, 3826-3826.	1.0	1
58	Endothelial dysfunction as predictor of angina recurrence after successful percutaneous coronary intervention using second generation drug eluting stents. European Journal of Preventive Cardiology, 2018, 25, 1360-1370.	0.8	9
59	Personalized treatment of myocardial infarction and non-obstructive coronary arteries: an unmet need in a high-risk population. European Heart Journal, 2018, 39, 3335-3335.	1.0	3
60	Epidemiology of Coronary Microvascular Obstruction. , 2018, , 53-68.		0
61	MINOCA: current perspectives. Aging, 2018, 10, 3044-3045.	1.4	2
62	Percutaneous coronary intervention in patients refused from surgery: a different entity?. Minerva Cardioangiologica, 2018, 66, 562-568.	1.2	3
63	Does prior percutaneous coronary intervention influence the outcome of coronary artery bypass grafting? One size does not fit all. Kardiologia Polska, 2018, 76, 933-934.	0.3	0
64	Procedural and 30â€day clinical outcomes following transcatheter aortic valve replacement with lotus valve: Results of the RELEVANT study. Catheterization and Cardiovascular Interventions, 2017, 90, 1206-1211.	0.7	12
65	Clinical outcome and correlates of coronary microvascular obstruction in latecomers after acute myocardial infarction. International Journal of Cardiology, 2017, 236, 30-35.	0.8	15
66	Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. Circulation, 2017, 135, 2145-2154.	1.6	45
67	Instantaneous Wave-free Ratio versus Fractional Flow Reserve. New England Journal of Medicine, 2017, 377, 1595-1599.	13.9	17
68	Microvascular obstruction is an independent predictor of major adverse cardiovascular events in latecomers after ST-elevation myocardial infarction. International Journal of Cardiology, 2017, 243, 109.	0.8	1
69	Angina after percutaneous coronary intervention: The need for precision medicine. International Journal of Cardiology, 2017, 248, 14-19.	0.8	51
70	Unprotected left main revascularization: Percutaneous coronary intervention versus coronary artery bypass. An updated systematic review and meta-analysis of randomised controlled trials. PLoS ONE, 2017, 12, e0179060.	1.1	13
71	Bioresorbable vascular scaffolds: between promises and reality. Oncotarget, 2017, 8, 69202-69203.	0.8	0
72	Transcatheter mitral valve regurgitation treatment: State of the art and a glimpse to the future. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 319-327.	0.4	31

#	Article	IF	CITATIONS
73	Transcatheter aortic valve replacement—state of the art and a glimpse to the future: †the Tailored Approach'. European Heart Journal Supplements, 2016, 18, E86-E95.	0.0	3
74	Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	17
75	Prognostic role of multiple biomarkers in stable patients undergoing fractional flow reserve-guided coronary angioplasty. Journal of Cardiovascular Medicine, 2016, 17, 687-693.	0.6	1
76	Persistence of Severe Pulmonary Hypertension After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	33
77	NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. Cardiovascular Revascularization Medicine, 2016, 17, 162-168.	0.3	10
78	Outcomes After Transcatheter Aortic Valve Replacement WithÂBalloon-Expandable Versus Self-Expandable Valves. Journal of the American College of Cardiology, 2016, 67, 235-236.	1.2	0
79	The failing right heart: implications and evolution in high-risk patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 12, 1542-1549.	1.4	16
80	Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. European Heart Journal, 2015, 36, 1377-1384.	1.0	226
81	Coronary In-Stent Restenosis in Patients Treated With Thoracic External Beam Radiation for Cancer. JACC: Cardiovascular Interventions, 2015, 8, 641.	1.1	0
82	Optical coherence tomography features of angiographic complex and smooth lesions in acute coronary syndromes. International Journal of Cardiovascular Imaging, 2015, 31, 927-934.	0.7	14
83	Neoatherosclerosis: a novel player in late stent failure. Interventional Cardiology, 2014, 6, 217-225.	0.0	1
84	Morphological–biohumoral correlations in acute coronary syndromes: Pathogenetic implications. International Journal of Cardiology, 2014, 171, 463-466.	0.8	31
85	Evolving management of patients treated by drug-eluting stent: Prevention of late events. Cardiovascular Revascularization Medicine, 2014, 15, 100-108.	0.3	1
86	Advances in mechanisms, imaging and management of the unstable plaque. Atherosclerosis, 2014, 233, 467-477.	0.4	41
87	Permanent polymer of drug eluting stents increases eosinophil cationic protein levels following percutaneous coronary intervention independently of C-reactive protein. Atherosclerosis, 2014, 237, 816-820.	0.4	3
88	Excimer laser for a highly stenotic saphenous vein graft: evidence of debulking by optical coherence tomography. EuroIntervention, 2014, 9, 1484-1484.	1.4	3
89	Access route for coronary chronic total occlusion: femoral or radial approach?. Interventional Cardiology, 2013, 5, 485-488.	0.0	1
90	Identification of unique adaptive immune system signature in acute coronary syndromes. International Journal of Cardiology, 2013, 168, 564-567.	0.8	31

#	Article	IF	CITATIONS
91	Inflammatory Mechanisms of Adverse Reactions to Drug-Eluting Stents. Current Vascular Pharmacology, 2013, 11, 392-398.	0.8	20
92	Incidence, time course and predictors of early vs. late target lesion revascularisation after everolimus-eluting stent implantation: a SPIRIT V substudy. EuroIntervention, 2013, 9, 353-359.	1.4	3
93	Letter by Montone et al Regarding Article, "Atrial Fibrillation: Outpatient Presentation and Management― Circulation, 2012, 125, e318; author reply e319.	1.6	0
94	Impact of electronegative low-density lipoprotein on angiographic coronary atherosclerotic burden. Atherosclerosis, 2012, 223, 166-170.	0.4	13
95	Very late stent thrombosis complicating a previously lost and partially crushed stent: Demonstration by optical coherence tomography. Cardiovascular Revascularization Medicine, 2012, 13, 357-359.	0.3	2
96	Eosinophils and risk stratification of patients treated by coronary stenting. Thrombosis Research, 2012, 130, 571-573.	0.8	2
97	Chlamydia pneumoniae in coronary atherosclerotic plaques and coronary instability. International Journal of Cardiology, 2011, 147, 176-178.	0.8	5
98	Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. European Heart Journal, 2011, 32, 1214-1226.	1.0	103
99	Response to Letter Regarding Article, "High Levels of Systemic Myeloperoxidase Are Associated With Coronary Plaque Erosion in Patients With Acute Coronary Syndromes: A Clinicopathological Study― Circulation, 2011, 124, .	1.6	1
100	Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation. Journal of Invasive Cardiology, 2011, 23, 16-20.	0.4	4
101	Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coronary Artery Disease, 2010, 21, 217-221.	0.3	43
102	Predictive value of C-reactive protein after drug-eluting stent implantation. Future Cardiology, 2010, 6, 167-179.	0.5	11
103	High Levels of Systemic Myeloperoxidase Are Associated With Coronary Plaque Erosion in Patients With Acute Coronary Syndromes. Circulation, 2010, 122, 2505-2513.	1.6	205
104	Stent for chronic total coronary occlusions: benefits and drawbacks after the introduction of drug-eluting stents. Interventional Cardiology, 2010, 2, 405-416.	0.0	2
105	The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation. Journal of the American College of Cardiology, 2010, 56, 1783-1793.	1.2	101
106	Accuracy of OCT in Evaluating Neointimal Thickness After Stent Implantation. JACC: Cardiovascular Imaging, 2010, 3, 669.	2.3	0
107	Eosinophil cationic protein: A new biomarker of coronary atherosclerosis. Atherosclerosis, 2010, 211, 606-611.	0.4	63
108	Optical coherence tomography follow-up of the subintimal tracking and re-entry technique for chronic total occlusion. EuroIntervention, 2010, 6, 662-663.	1.4	4

#	Article	IF	CITATIONS
109	Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. European Heart Journal, 2009, 30, 1340-1347.	1.0	51
110	Carotid bruits and cardiovascular death or myocardial infarction. Lancet, The, 2008, 372, 534.	6.3	0
111	Editorial: MINOCA: Pathogenesis, Diagnosis, Clinical Management and Evolution Towards Precision Medicine. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0